{"pmid":32294285,"title":"Liver impairment associated with disease progression in COVID-19 patients.","text":["Liver impairment associated with disease progression in COVID-19 patients.","We read with great interest the study by YF Zhang et al ([1]) . The authors found that abnormalities of liver function tests are common in COVID-19 patients, but the clinically significant liver dysfunction in COVID-19 was not a prominent feature of this illness and also may not have serious clinical consequences. This study is important and interesting; however, we still have some concerns about it.","Liver Int","Chen, Peng","Lei, Jiexin","Wu, Yue","Liu, Gang","Zhou, Benhong","32294285"],"abstract":["We read with great interest the study by YF Zhang et al ([1]) . The authors found that abnormalities of liver function tests are common in COVID-19 patients, but the clinically significant liver dysfunction in COVID-19 was not a prominent feature of this illness and also may not have serious clinical consequences. This study is important and interesting; however, we still have some concerns about it."],"journal":"Liver Int","authors":["Chen, Peng","Lei, Jiexin","Wu, Yue","Liu, Gang","Zhou, Benhong"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294285","week":"202016|Apr 13 - Apr 19","doi":"10.1111/liv.14481","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664266295768514560,"score":8.233237,"similar":[{"pmid":32239796,"title":"Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China.","text":["Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China.","BACKGROUND: The SARS-CoV-2 pandemic is an ongoing global health emergency. The aim of our study was to investigate the changes of liver function and its clinical significance in COVID-19 patients. METHOD: This retrospective, single-center study was conducted on 115 confirmed cases of COVID-19 in Zhongnan hospital of Wuhan University from Jan 18 to Feb 22, 2020. Liver function and related indexes were analyzed to evaluate its relationship with disease progression in COVID-19 patients. RESULTS: Part of the COVID-19 patients presented with varying degrees of abnormality in liver function indexes. However, the levels of ALT, AST, TBIL, GGT and LDH in COVID-19 patients were not significantly different in compared with hospitalized community-acquired pneumonia patients, and the levels of albumin is even significantly higher. Levels of ALT, AST, TBIL, LDH and INR showed statistically significant elevation in severe COVID-19 cases compared with that in mild cases. However, the clinical significance of the elevation is unremarkable. Majority of severe COVID-19 patients showed significantly decreasing in albumin level and continuously decreasing in the progress of illness. Most of the liver function indexes in COVID-19 patients were correlated with CRP and NLR, the markers of inflammation. Logistic regression analysis further identified NLR as the independent risk factor for severe COVID-19, as well as age. CONCLUSIONS: Although abnormalities of liver function indexes are common in COVID-19 patients, the impairment of liver function is not a prominent feature of COVID-19, and also may not have serious clinical consequences.","Liver Int","Zhang, Yafei","Zheng, Liang","Liu, Lan","Zhao, Mengya","Xiao, Jun","Zhao, Qiu","32239796"],"abstract":["BACKGROUND: The SARS-CoV-2 pandemic is an ongoing global health emergency. The aim of our study was to investigate the changes of liver function and its clinical significance in COVID-19 patients. METHOD: This retrospective, single-center study was conducted on 115 confirmed cases of COVID-19 in Zhongnan hospital of Wuhan University from Jan 18 to Feb 22, 2020. Liver function and related indexes were analyzed to evaluate its relationship with disease progression in COVID-19 patients. RESULTS: Part of the COVID-19 patients presented with varying degrees of abnormality in liver function indexes. However, the levels of ALT, AST, TBIL, GGT and LDH in COVID-19 patients were not significantly different in compared with hospitalized community-acquired pneumonia patients, and the levels of albumin is even significantly higher. Levels of ALT, AST, TBIL, LDH and INR showed statistically significant elevation in severe COVID-19 cases compared with that in mild cases. However, the clinical significance of the elevation is unremarkable. Majority of severe COVID-19 patients showed significantly decreasing in albumin level and continuously decreasing in the progress of illness. Most of the liver function indexes in COVID-19 patients were correlated with CRP and NLR, the markers of inflammation. Logistic regression analysis further identified NLR as the independent risk factor for severe COVID-19, as well as age. CONCLUSIONS: Although abnormalities of liver function indexes are common in COVID-19 patients, the impairment of liver function is not a prominent feature of COVID-19, and also may not have serious clinical consequences."],"journal":"Liver Int","authors":["Zhang, Yafei","Zheng, Liang","Liu, Lan","Zhao, Mengya","Xiao, Jun","Zhao, Qiu"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32239796","week":"202014|Mar 30 - Apr 05","doi":"10.1111/liv.14455","keywords":["COVID-19","SARS-CoV-2","Wuhan","clinical significance","liver function"],"source":"PubMed","locations":["Zhongnan","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1663352135567278080,"score":249.24464},{"pmid":32283325,"title":"Clinical Features of COVID-19-Related Liver Damage.","text":["Clinical Features of COVID-19-Related Liver Damage.","BACKGROUND & AIMS: Some patients with SARS-CoV-2 infection have abnormal liver function. We aimed to clarify the features of COVID-19-related liver damage to provide references for clinical treatment. METHODS: We performed a retrospective, single-center study of 148 consecutive patients with confirmed COVID-19 (73 female, 75 male; mean age, 50 years) at the Shanghai Public Health Clinical Center from January 20 through January 31, 2020. Patient outcomes were followed until February 19, 2020. Patients were analyzed for clinical features, laboratory parameters (including liver function tests), medications, and length of hospital stay. Abnormal liver function was defined as increased levels of alanine and aspartate aminotransferase, gamma glutamyltransferase, alkaline phosphatase, and total bilirubin. RESULTS: Fifty-five patients (37.2%) had abnormal liver function at hospital admission; 14.5% of these patients had high fever (14.5%), compared with 4.3% of patients with normal liver function (P=.027). Patients with abnormal liver function were more likely to be male, and had higher levels of procalcitonin and C-reactive protein. There was no statistical difference between groups in medications taken before hospitalization; a significantly higher proportion of patients with abnormal liver function (57.8%) had received lopinavir/ritonavir after admission compared to patients with normal liver function (31.3%). Patients with abnormal liver function had longer mean hospital stays (15.09+/-4.79 days) than patients with normal liver function (12.76+/-4.14 days) (P=.021). CONCLUSIONS: More than one third of patients admitted to the hospital with SARS-CoV-2 infection have abnormal liver function, and this is associated with longer hospital stay. A significantly higher proportion of patients with abnormal liver function had received lopinavir/ritonavir after admission; these drugs should be given with caution.","Clin Gastroenterol Hepatol","Fan, Zhenyu","Chen, Liping","Li, Jun","Cheng, Xin","Jingmao Yang","Tian, Cheng","Zhang, Yajun","Huang, Shaoping","Liu, Zhanju","Cheng, Jilin","32283325"],"abstract":["BACKGROUND & AIMS: Some patients with SARS-CoV-2 infection have abnormal liver function. We aimed to clarify the features of COVID-19-related liver damage to provide references for clinical treatment. METHODS: We performed a retrospective, single-center study of 148 consecutive patients with confirmed COVID-19 (73 female, 75 male; mean age, 50 years) at the Shanghai Public Health Clinical Center from January 20 through January 31, 2020. Patient outcomes were followed until February 19, 2020. Patients were analyzed for clinical features, laboratory parameters (including liver function tests), medications, and length of hospital stay. Abnormal liver function was defined as increased levels of alanine and aspartate aminotransferase, gamma glutamyltransferase, alkaline phosphatase, and total bilirubin. RESULTS: Fifty-five patients (37.2%) had abnormal liver function at hospital admission; 14.5% of these patients had high fever (14.5%), compared with 4.3% of patients with normal liver function (P=.027). Patients with abnormal liver function were more likely to be male, and had higher levels of procalcitonin and C-reactive protein. There was no statistical difference between groups in medications taken before hospitalization; a significantly higher proportion of patients with abnormal liver function (57.8%) had received lopinavir/ritonavir after admission compared to patients with normal liver function (31.3%). Patients with abnormal liver function had longer mean hospital stays (15.09+/-4.79 days) than patients with normal liver function (12.76+/-4.14 days) (P=.021). CONCLUSIONS: More than one third of patients admitted to the hospital with SARS-CoV-2 infection have abnormal liver function, and this is associated with longer hospital stay. A significantly higher proportion of patients with abnormal liver function had received lopinavir/ritonavir after admission; these drugs should be given with caution."],"journal":"Clin Gastroenterol Hepatol","authors":["Fan, Zhenyu","Chen, Liping","Li, Jun","Cheng, Xin","Jingmao Yang","Tian, Cheng","Zhang, Yajun","Huang, Shaoping","Liu, Zhanju","Cheng, Jilin"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283325","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.cgh.2020.04.002","keywords":["ALP","Antiviral drug","Prognosis","liver injury"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"e_drugs":["lopinavir-ritonavir drug combination"],"_version_":1664182200818466816,"score":164.54744},{"pmid":32302212,"title":"COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation.","text":["COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation.","We present a case of COVID-19 hepatitis in a living donor liver allograft recipient whose donor subsequently tested positive for COVID-19. The patient is a female infant with biliary atresia (failed Kasai procedure). She recovered well, with improving liver function tests for 4 days. On post-operative day (POD) 4 the patient developed respiratory distress and fever. COVID-19 testing (polymerase chain reaction) was positive. Liver function tests increased approximately 5-fold. Liver biopsy showed moderate acute hepatitis with prominent clusters of apoptotic hepatocytes and associated cellular debris. Lobular lymphohistiocytic inflammation was noted. Typical portal features of mild to moderate acute cellular rejection were also noted.","Arch Pathol Lab Med","Lagana, Stephen M","De Michele, Simona","Lee, Michael J","Emond, Jean C","Griesemer, Adam D","Tulin-Silver, Sheryl A","Verna, Elizabeth C","Martinez, Mercedes","Lefkowitch, Jay H","32302212"],"abstract":["We present a case of COVID-19 hepatitis in a living donor liver allograft recipient whose donor subsequently tested positive for COVID-19. The patient is a female infant with biliary atresia (failed Kasai procedure). She recovered well, with improving liver function tests for 4 days. On post-operative day (POD) 4 the patient developed respiratory distress and fever. COVID-19 testing (polymerase chain reaction) was positive. Liver function tests increased approximately 5-fold. Liver biopsy showed moderate acute hepatitis with prominent clusters of apoptotic hepatocytes and associated cellular debris. Lobular lymphohistiocytic inflammation was noted. Typical portal features of mild to moderate acute cellular rejection were also noted."],"journal":"Arch Pathol Lab Med","authors":["Lagana, Stephen M","De Michele, Simona","Lee, Michael J","Emond, Jean C","Griesemer, Adam D","Tulin-Silver, Sheryl A","Verna, Elizabeth C","Martinez, Mercedes","Lefkowitch, Jay H"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302212","week":"202016|Apr 13 - Apr 19","doi":"10.5858/arpa.2020-0186-SA","source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664357978684260354,"score":156.49118},{"pmid":32298767,"title":"Characteristics of Liver Tests in COVID-19 Patients.","text":["Characteristics of Liver Tests in COVID-19 Patients.","BACKGROUND & AIMS: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver tests. METHODS: Clinical records and laboratory results were obtained from 417 laboratory-confirmed COVID-19 patients who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information of clinical features of patients with abnormal liver tests were collected for analysis. RESULTS: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients raising liver enzyme levels to more than 3 times of upper limit units in alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase, respectively. Patients with abnormal liver test of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios (OR)=2.73, 95% confidence interval (CI) 1.19-6.3, and 4.44, 95% CI 1.93-10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both P<0.01). CONCLUSION: Patients with abnormal liver tests had higher risks of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, should be monitored and evaluated frequently.","J Hepatol","Cai, Qingxian","Huang, Deliang","Yu, Hong","Zhu, Zhibin","Xia, Zhang","Su, Yinan","Li, Zhiwei","Zhou, Guangde","Gou, Jizhou","Qu, Jiuxin","Sun, Yan","Liu, Yingxia","He, Qing","Chen, Jun","Liu, Lei","Xu, Lin","32298767"],"abstract":["BACKGROUND & AIMS: Recent data on the coronavirus disease 2019 (COVID-19) outbreak caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to shine light on the impact of the disease on the liver. But no studies to date have systematically described liver test abnormalities in patients with COVID-19. We evaluated the clinical characteristics of COVID-19 in patients with abnormal liver tests. METHODS: Clinical records and laboratory results were obtained from 417 laboratory-confirmed COVID-19 patients who were admitted to the only referral hospital in Shenzhen, China from January 11 to February 21, 2020 and followed up to March 7, 2020. Information of clinical features of patients with abnormal liver tests were collected for analysis. RESULTS: Of 417 patients with COVID-19, 318 (76.3%) had abnormal liver test results and 90 (21.5%) had liver injury during hospitalization. The presence of abnormal liver tests became more pronounced during hospitalization within 2 weeks, with 49 (23.4%), 31 (14.8%), 24 (11.5%) and 51 (24.4%) patients raising liver enzyme levels to more than 3 times of upper limit units in alanine aminotransferase, aspartate aminotransferase, total bilirubin and gamma-glutamyl transferase, respectively. Patients with abnormal liver test of hepatocellular type or mixed type at admission had higher odds of progressing to severe disease (odds ratios (OR)=2.73, 95% confidence interval (CI) 1.19-6.3, and 4.44, 95% CI 1.93-10.23, respectively). The use of lopinavir/ritonavir was also found to lead to increased odds of liver injury (OR from 4.44 to 5.03, both P<0.01). CONCLUSION: Patients with abnormal liver tests had higher risks of progressing to severe disease. The detrimental effects on liver injury mainly related to certain medications used during hospitalization, should be monitored and evaluated frequently."],"journal":"J Hepatol","authors":["Cai, Qingxian","Huang, Deliang","Yu, Hong","Zhu, Zhibin","Xia, Zhang","Su, Yinan","Li, Zhiwei","Zhou, Guangde","Gou, Jizhou","Qu, Jiuxin","Sun, Yan","Liu, Yingxia","He, Qing","Chen, Jun","Liu, Lei","Xu, Lin"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298767","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jhep.2020.04.006","keywords":["COVID-19","Liver Tests","Liver injury","SARS-Cov-2"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Shenzhen","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664266651172864000,"score":153.98853},{"pmid":32153170,"title":"[Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region].","text":["[Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region].","Objective: To understand the clinical characteristics, change of liver function, influencing factors and prognosis in hospitalized patients with coronavirus disease-19 (COVID-19) combined with liver injury. Methods: The general conditions, biochemical indicators of liver, blood clotting mechanism, routine blood test, UGT1A1 * 28 gene polymorphism and other data of 40 cases with COVID-19 admitted to the isolation ward of Tangdu Hospital were retrospectively analyzed. The clinical characteristics, influencing factors and prognosis of liver injury in patients with liver injury group and those with normal liver function group were compared. The mean of two samples in univariate analysis was compared by t-test and analysis of variance. The counting data was measured by chi(2) tests. The non-normal distribution measurement data were described by the median, and the non-parametric test was used. Statistically significant influencing factors were used as the independent variables in univariate analysis. Multiple logistic regression analysis was used to analyze the main influencing factors of liver injury. Results: Of the 40 cases, 25 were male (62.5%) and 15 were female (37.5%), aged 22 to 83 (53.87 +/- 15.84) years. Liver injury was occurred in 22 cases (55%) during the course of the disease. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level was initially increased (4.4 to 3.5 times of the normal value) along with decrease of albumin in the second week, and the difference was statistically significant (P < 0.001). Ten cases (43.5%) had highest abnormal total blood bilirubin (54.1 mumol/ L). There was no correlation between the increase in transaminase and the increase in total blood bilirubin (R = -0.006, P = 0.972). Three cases had prothrombin activity (PTA) of </= 50%, 10 cases had elevated FDP, and 13 cases had elevated D-dimer, all of whom were severe or critically ill. Liver function injury was more likely to occur in patients who used many types of drugs and large amounts of hormones (P = 0.002, P = 0.031), and there was no correlation with the TA6TA7 mutation in the UGT1A1 * 28 gene locus. Multiple regression analysis showed that the occurrence of liver injury was only related to critical illness. The liver function of all patients had recovered within one week after conventional liver protection treatment. Conclusion: COVID-19 combined with liver function injury may be due to the slight elevation of transaminase, mostly around the second week of the disease course. Severe patients have a higher proportion of liver injury, and critical type is an independent risk factor for liver injury.","Zhonghua Gan Zang Bing Za Zhi","Yao, N","Wang, S N","Lian, J Q","Sun, Y T","Zhang, G F","Kang, W Z","Kang, W","32153170"],"abstract":["Objective: To understand the clinical characteristics, change of liver function, influencing factors and prognosis in hospitalized patients with coronavirus disease-19 (COVID-19) combined with liver injury. Methods: The general conditions, biochemical indicators of liver, blood clotting mechanism, routine blood test, UGT1A1 * 28 gene polymorphism and other data of 40 cases with COVID-19 admitted to the isolation ward of Tangdu Hospital were retrospectively analyzed. The clinical characteristics, influencing factors and prognosis of liver injury in patients with liver injury group and those with normal liver function group were compared. The mean of two samples in univariate analysis was compared by t-test and analysis of variance. The counting data was measured by chi(2) tests. The non-normal distribution measurement data were described by the median, and the non-parametric test was used. Statistically significant influencing factors were used as the independent variables in univariate analysis. Multiple logistic regression analysis was used to analyze the main influencing factors of liver injury. Results: Of the 40 cases, 25 were male (62.5%) and 15 were female (37.5%), aged 22 to 83 (53.87 +/- 15.84) years. Liver injury was occurred in 22 cases (55%) during the course of the disease. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level was initially increased (4.4 to 3.5 times of the normal value) along with decrease of albumin in the second week, and the difference was statistically significant (P < 0.001). Ten cases (43.5%) had highest abnormal total blood bilirubin (54.1 mumol/ L). There was no correlation between the increase in transaminase and the increase in total blood bilirubin (R = -0.006, P = 0.972). Three cases had prothrombin activity (PTA) of </= 50%, 10 cases had elevated FDP, and 13 cases had elevated D-dimer, all of whom were severe or critically ill. Liver function injury was more likely to occur in patients who used many types of drugs and large amounts of hormones (P = 0.002, P = 0.031), and there was no correlation with the TA6TA7 mutation in the UGT1A1 * 28 gene locus. Multiple regression analysis showed that the occurrence of liver injury was only related to critical illness. The liver function of all patients had recovered within one week after conventional liver protection treatment. Conclusion: COVID-19 combined with liver function injury may be due to the slight elevation of transaminase, mostly around the second week of the disease course. Severe patients have a higher proportion of liver injury, and critical type is an independent risk factor for liver injury."],"journal":"Zhonghua Gan Zang Bing Za Zhi","authors":["Yao, N","Wang, S N","Lian, J Q","Sun, Y T","Zhang, G F","Kang, W Z","Kang, W"],"date":"2020-03-11T11:00:00Z","year":2020,"_id":"32153170","week":"202011|Mar 09 - Mar 15","doi":"10.3760/cma.j.cn501113-20200226-00070","keywords":["COVID-19","Clinical characteristics","Liver function","Liver injury","Prognosis","Risk factor"],"source":"PubMed","locations":["Shaanxi"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"e_drugs":["Bilirubin"],"_version_":1663352134100320256,"score":142.1034}]}